Functionally, RECQL4 knockdown sensitizes tumor cells to ATR inhibition, suggesting a potential therapeutic vulnerability in the clinical setting and possibly, a diagnostic role of RECQL4 IHC for treatment selection. The gene discussed is ATR; the disease is neoplasm.